Limits...
Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients.

Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y - Gastroenterol Res Pract (2014)

Bottom Line: The baseline and treatment-related factors potentially associated with SVR were determined by multivariate logistic regression analysis.Achievement of a rapid virological response (RVR), defined as undetectable HCV RNA at week 4 of treatment, was identified as an after-starting-treatment predictor (P = 2.47 × 10(-5)).However, neither a substitution in core aa 70 nor the number of substitutions in the ISDR affected treatment outcome.

View Article: PubMed Central - PubMed

Affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine Katsushika Medical Center, 6-41-2 Aoto, Katsushika-ku, Tokyo 125-0062, Japan.

ABSTRACT
We evaluated the genetic variation in rs8099917, substitutions in core amino acid (aa) 70, and the number of aa substitutions in the interferon sensitivity-determining region (ISDR) on the prediction of sustained virological response (SVR) in treatment-naïve hepatitis C virus (HCV) genotype 1b (G1b) patients. This multicenter study involved 150 Asian treatment-naïve patients infected with HCV G1b who received 12 weeks of telaprevir in combination with 24 weeks of peginterferon-α-2b and ribavirin. The baseline and treatment-related factors potentially associated with SVR were determined by multivariate logistic regression analysis. Virological response was analyzed on an intent-to-treat basis. Cessation of the therapy due to adverse effects occurred in only 2 patients, who discontinued the trial at 10 weeks and at 2 weeks due to cerebral infarction and renal impairment, respectively. Among the 150 patients in whom the final virological response was determined, only genotype TT in rs8099917 was identified as a pretreatment predictor (P = 7.38 × 10(-4)). Achievement of a rapid virological response (RVR), defined as undetectable HCV RNA at week 4 of treatment, was identified as an after-starting-treatment predictor (P = 2.47 × 10(-5)). However, neither a substitution in core aa 70 nor the number of substitutions in the ISDR affected treatment outcome.

No MeSH data available.


Related in: MedlinePlus

There was no significant relation between sustained virological response rate and age. The patients older than 65 years had hemoglobin levels similar to those aged ≤65 years.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4150495&req=5

fig2: There was no significant relation between sustained virological response rate and age. The patients older than 65 years had hemoglobin levels similar to those aged ≤65 years.

Mentions: Among the 150 patients, 29 (19.3%) were aged >65 years. The frequency of the non-TT genotype (TG or GG) rs8099917 in the patients in both age groups was similar. However, the frequency of cirrhosis in patients aged over 65 years (9/29; 31.0%) was higher than that in the younger patients (20/121; 16.5%). The SVR rate in the older (aged >65 years) patients was similar to that in those aged ≤65 years, regardless of the rs8099917 genotype or the existence of cirrhosis (Figure 2). In 29 patients aged >65 years, the frequencies of the major side effect were as follows: anemia occurred in 28 (96.6%), elevation of serum uric acid in 20 (69.0%), skin rashes in 18 (62.1%), headache in 15 (51.7%), nausea in 11 (37.9%), and elevation of serum creatinine in 10 (34.4%). The frequencies were similar to those of the ≤65 years patients. Cessation of the therapy due to adverse effects occurred in only 1 (3.4%) patient; this patient discontinued the therapy at 10 weeks due to renal impairment (data not shown).


Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients.

Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y - Gastroenterol Res Pract (2014)

There was no significant relation between sustained virological response rate and age. The patients older than 65 years had hemoglobin levels similar to those aged ≤65 years.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4150495&req=5

fig2: There was no significant relation between sustained virological response rate and age. The patients older than 65 years had hemoglobin levels similar to those aged ≤65 years.
Mentions: Among the 150 patients, 29 (19.3%) were aged >65 years. The frequency of the non-TT genotype (TG or GG) rs8099917 in the patients in both age groups was similar. However, the frequency of cirrhosis in patients aged over 65 years (9/29; 31.0%) was higher than that in the younger patients (20/121; 16.5%). The SVR rate in the older (aged >65 years) patients was similar to that in those aged ≤65 years, regardless of the rs8099917 genotype or the existence of cirrhosis (Figure 2). In 29 patients aged >65 years, the frequencies of the major side effect were as follows: anemia occurred in 28 (96.6%), elevation of serum uric acid in 20 (69.0%), skin rashes in 18 (62.1%), headache in 15 (51.7%), nausea in 11 (37.9%), and elevation of serum creatinine in 10 (34.4%). The frequencies were similar to those of the ≤65 years patients. Cessation of the therapy due to adverse effects occurred in only 1 (3.4%) patient; this patient discontinued the therapy at 10 weeks due to renal impairment (data not shown).

Bottom Line: The baseline and treatment-related factors potentially associated with SVR were determined by multivariate logistic regression analysis.Achievement of a rapid virological response (RVR), defined as undetectable HCV RNA at week 4 of treatment, was identified as an after-starting-treatment predictor (P = 2.47 × 10(-5)).However, neither a substitution in core aa 70 nor the number of substitutions in the ISDR affected treatment outcome.

View Article: PubMed Central - PubMed

Affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine Katsushika Medical Center, 6-41-2 Aoto, Katsushika-ku, Tokyo 125-0062, Japan.

ABSTRACT
We evaluated the genetic variation in rs8099917, substitutions in core amino acid (aa) 70, and the number of aa substitutions in the interferon sensitivity-determining region (ISDR) on the prediction of sustained virological response (SVR) in treatment-naïve hepatitis C virus (HCV) genotype 1b (G1b) patients. This multicenter study involved 150 Asian treatment-naïve patients infected with HCV G1b who received 12 weeks of telaprevir in combination with 24 weeks of peginterferon-α-2b and ribavirin. The baseline and treatment-related factors potentially associated with SVR were determined by multivariate logistic regression analysis. Virological response was analyzed on an intent-to-treat basis. Cessation of the therapy due to adverse effects occurred in only 2 patients, who discontinued the trial at 10 weeks and at 2 weeks due to cerebral infarction and renal impairment, respectively. Among the 150 patients in whom the final virological response was determined, only genotype TT in rs8099917 was identified as a pretreatment predictor (P = 7.38 × 10(-4)). Achievement of a rapid virological response (RVR), defined as undetectable HCV RNA at week 4 of treatment, was identified as an after-starting-treatment predictor (P = 2.47 × 10(-5)). However, neither a substitution in core aa 70 nor the number of substitutions in the ISDR affected treatment outcome.

No MeSH data available.


Related in: MedlinePlus